Clinical Trial Update: Trabectedin First Line Therapy In Unfit Sarcoma Study [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trabectedin as first-line therapy in patients with metastatic or locally advanced soft tissue sarcoma who are unfit for standard chemot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Trabectedin (Yondelis) (trabectedin)

Snippet

Sponsor: Italian Sarcoma Group | Conditions: Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive, Standard Chemotherapy | Phase 2 | Status: COMPLETED